Over time, molecular biology and genomics techniques have been developed to speed up
the early diagnosis and clinical management of cancer. These therapies are often most …

Translational research of liquid biopsy is just at the edge of routine clinical application: an
emerging validity of circulating tumor DNA (ctDNA) tests suggests its use for earlier cancer …

There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC)
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …

Liquid biopsy recently became a very promising diagnostic method that has several
advantages over conventional invasive methods. Liquid biopsy may serve as a source of …

Highlights•Cell-free nucleic acids in body fluids contain tumour fragments that can be
profiled for prognostic and diagnostic information for the management of cancer.•cfDNA …

Circulating cell-free DNA (cfDNA) refers to extracellular DNA present in body fluid that may
be derived from both normal and diseased cells. The concentration, integrity, genetic, and …

Simple Summary Cell-free DNA—DNA that has been expelled from cells and can be
isolated from blood plasma and other body fluids—is a useful tool in medicine, with …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

Hepatocellular carcinoma (HCC) is a severe neoplastic disease associated with high
morbidity and mortality rates. HCC is often detected at advanced stages leading to …

In the course of the search for new biomarkers, circulating cell-free DNA (ccf-DNA) has
become a popular target of interest. An elevated level of ccf-DNA has been detected in the …